Bavarian Nordic To Take Prostvac Prostate Cancer Vaccine Into Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Bavarian Nordic's attempt to reduce the risk associated with developing a cancer vaccine includes licensing a vetted therapy from the National Cancer Institute and developing it with the institute under a Cooperative Research and Development Agreement.
You may also be interested in...
Therion no longer plans to submit a BLA for its PANVAC-VF pancreatic cancer treatment.
THERION/NCI CANCER IMMUNOTHERAPEUTICS CRADA calls for Therion to "generate vaccine candidates based on live recombinant poxvirus vectors that express specific tumor-associated antigens" characterized by the National Cancer Institute, the privately held Cambridge, Mass.-based company announced Nov. 1. NCI Surgery Branch Chief Steven Rosenberg, MD/PhD, will be the agency's principal investigator for the five-year collaboration.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.